FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors

[first paragraph of article]The 2003 discovery of proprotein convertase subtilisin–kexin type-9 (PCSK9) – a circulating protein targeting the low density lipoprotein (LDL) receptor for its degradation – paved the way for the development of several therapeutic approaches which inhibit the protein itself (by monoclonal antibodies) or its RNA (by RNA interference ‘‘RNAi’’). These drugs are a very promising and attractive therapy for high- risk cardiovascular (CV) patients, patients with statin intolerance, and those with familial hypercholesterolemia.